These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 15744351)
21. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols. Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436 [TBL] [Abstract][Full Text] [Related]
22. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Ravandi F; Jorgensen JL; Thomas DA; O'Brien S; Garris R; Faderl S; Huang X; Wen S; Burger JA; Ferrajoli A; Kebriaei P; Champlin RE; Estrov Z; Challagundla P; Wang SA; Luthra R; Cortes JE; Kantarjian HM Blood; 2013 Aug; 122(7):1214-21. PubMed ID: 23836561 [TBL] [Abstract][Full Text] [Related]
23. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP; N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335 [TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416 [TBL] [Abstract][Full Text] [Related]
25. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia. Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293 [TBL] [Abstract][Full Text] [Related]
26. Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring. Zaliova M; Fronkova E; Krejcikova K; Muzikova K; Mejstrikova E; Stary J; Trka J; Zuna J Leukemia; 2009 May; 23(5):944-51. PubMed ID: 19158828 [TBL] [Abstract][Full Text] [Related]
27. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450 [TBL] [Abstract][Full Text] [Related]
28. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599 [TBL] [Abstract][Full Text] [Related]
29. [The monitoring of BCR-ABL mRNA by reverse transcription PCR in patients undergoing allogeneic bone marrow transplantation for acute lymphoblastic leukemia with a positive Philadelphia chromosome]. Román J; Castillejo JA; Jiménez A; Maldonado J; Torres A Med Clin (Barc); 1999 Dec; 113(20):779-82. PubMed ID: 10680143 [TBL] [Abstract][Full Text] [Related]
30. [Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation followed by maintenance therapy. Experience of a single center]. Doubek M; Mayer J; Korístek Z; Protivánková M; Brychtová Y; Oborilová A; Král Z; Klabusay M; Tomíska M; Buchtová I; Vorlícek J Cas Lek Cesk; 2002 Mar; 141(4):122-6. PubMed ID: 12046256 [TBL] [Abstract][Full Text] [Related]
31. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765 [TBL] [Abstract][Full Text] [Related]
32. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099 [TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971 [TBL] [Abstract][Full Text] [Related]
34. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. Dombret H; Gabert J; Boiron JM; Rigal-Huguet F; Blaise D; Thomas X; Delannoy A; Buzyn A; Bilhou-Nabera C; Cayuela JM; Fenaux P; Bourhis JH; Fegueux N; Charrin C; Boucheix C; Lhéritier V; Espérou H; MacIntyre E; Vernant JP; Fière D; Blood; 2002 Oct; 100(7):2357-66. PubMed ID: 12239143 [TBL] [Abstract][Full Text] [Related]
35. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714 [TBL] [Abstract][Full Text] [Related]
36. Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia. Martin H; Atta J; Zumpe P; Eder M; Elsner S; Rode C; Wassmann B; Bruecher J; Hoelzer D Exp Hematol; 1995 Dec; 23(14):1612-8. PubMed ID: 8542955 [TBL] [Abstract][Full Text] [Related]
37. Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome. Chen ZX; Kaeda J; Saunders S; Goldman JM Chin Med J (Engl); 2004 Jul; 117(7):968-71. PubMed ID: 15265366 [TBL] [Abstract][Full Text] [Related]